JPWO2021173832A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021173832A5 JPWO2021173832A5 JP2022550848A JP2022550848A JPWO2021173832A5 JP WO2021173832 A5 JPWO2021173832 A5 JP WO2021173832A5 JP 2022550848 A JP2022550848 A JP 2022550848A JP 2022550848 A JP2022550848 A JP 2022550848A JP WO2021173832 A5 JPWO2021173832 A5 JP WO2021173832A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- cancer
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 42
- 206010028980 Neoplasm Diseases 0.000 claims 25
- 201000011510 cancer Diseases 0.000 claims 25
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 14
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 14
- 229940127121 immunoconjugate Drugs 0.000 claims 10
- 238000011374 additional therapy Methods 0.000 claims 5
- 229960000106 biosimilars Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 230000003321 amplification Effects 0.000 claims 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims 3
- 229960000575 trastuzumab Drugs 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 238000007481 next generation sequencing Methods 0.000 claims 2
- 229960002087 pertuzumab Drugs 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 239000000611 antibody drug conjugate Substances 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
- 238000003782 apoptosis assay Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000002681 cryosurgery Methods 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000007492 gastroesophageal junction adenocarcinoma Diseases 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062981355P | 2020-02-25 | 2020-02-25 | |
| US62/981,355 | 2020-02-25 | ||
| US202063105104P | 2020-10-23 | 2020-10-23 | |
| US63/105,104 | 2020-10-23 | ||
| PCT/US2021/019667 WO2021173832A1 (en) | 2020-02-25 | 2021-02-25 | Cancer treatment methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519807A JP2023519807A (ja) | 2023-05-15 |
| JPWO2021173832A5 true JPWO2021173832A5 (zh) | 2024-02-26 |
Family
ID=75143716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550848A Pending JP2023519807A (ja) | 2020-02-25 | 2021-02-25 | 癌治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230165968A1 (zh) |
| EP (1) | EP4110403A1 (zh) |
| JP (1) | JP2023519807A (zh) |
| KR (1) | KR20220145871A (zh) |
| AU (1) | AU2021226570A1 (zh) |
| CA (1) | CA3169117A1 (zh) |
| WO (1) | WO2021173832A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| EP1272526A4 (en) | 2000-04-13 | 2004-10-13 | Univ Rockefeller | REINFORCING ANTIBODY-IMMUNE RESPONSE |
| US20070014795A1 (en) | 2004-12-30 | 2007-01-18 | Dhodapkar Madhav V | Compositions and methods for enhanced dendritic cell maturation and function |
| EP2455100A3 (en) | 2005-11-07 | 2012-11-07 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
| BR112017010110A2 (pt) | 2014-11-21 | 2018-01-30 | Bristol-Myers Squibb Company | anticorpos contra cd73 e usos do mesmo |
| WO2018009916A1 (en) * | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| JP2021524447A (ja) * | 2018-05-17 | 2021-09-13 | ボルト バイオセラピューティクス、インコーポレーテッド | イムノコンジュゲート |
| WO2020190731A1 (en) * | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| WO2020190734A1 (en) * | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting pd-l1 |
| WO2020190762A1 (en) * | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Macromolecule-supported tlr agonists |
| JP2022525594A (ja) * | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| WO2020190760A1 (en) * | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting cea |
-
2021
- 2021-02-25 EP EP21713788.4A patent/EP4110403A1/en active Pending
- 2021-02-25 CA CA3169117A patent/CA3169117A1/en active Pending
- 2021-02-25 AU AU2021226570A patent/AU2021226570A1/en active Pending
- 2021-02-25 JP JP2022550848A patent/JP2023519807A/ja active Pending
- 2021-02-25 US US17/802,392 patent/US20230165968A1/en active Pending
- 2021-02-25 KR KR1020227032892A patent/KR20220145871A/ko unknown
- 2021-02-25 WO PCT/US2021/019667 patent/WO2021173832A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6385277B2 (ja) | 癌治療のための抗ｃｅａｃａｍ１組換え型抗体 | |
| JP6170496B2 (ja) | Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用 | |
| JP2024054226A (ja) | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 | |
| TW201806616A (zh) | 抗－ｐｄ－１抗體與輻射治療癌症之組合 | |
| TWI822822B (zh) | 抗體-藥物結合物之用途 | |
| JP7471227B2 (ja) | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 | |
| JP2021167324A (ja) | がん治療のための集中インターフェロン免疫療法 | |
| JP2023025036A (ja) | がんの処置のためのアベルマブの投与レジメン | |
| JP7104153B2 (ja) | 癌を治療するための抗プロガストリン抗体と免疫療法の併用療法 | |
| JP2023554422A (ja) | がんの治療のための多重特異性抗体 | |
| JPWO2021173832A5 (zh) | ||
| WO2023227115A1 (en) | A method of treating solid tumor | |
| US20230398229A1 (en) | Antibody drug conjugates comprising sting agonists, combinations and methods of use | |
| US20230061858A1 (en) | Treatment with site specific her2 antibody-drug conjugates | |
| US20220218838A1 (en) | Adc for a treatment concomitant with or subsequent to docetaxel | |
| CN116333125A (zh) | 结合死亡受体4和死亡受体5的抗体 | |
| TW202306588A (zh) | 抗體-藥物結合物與免疫檢查點抑制劑組合用於治療泌尿上皮癌之用途 | |
| TW202323298A (zh) | 靶向ｎｋｇ２ａ之癌症療法 | |
| JP2024513138A (ja) | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 | |
| CN115461362A (zh) | 基于ICOS抗体和PD-L1抗体TGF-β受体融合蛋白的癌症组合疗法 | |
| JPWO2020061337A5 (zh) |